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	 Abstract
Introduction: Endometrial carcinoma is a common malignancy of the female genital tract. There is a strong 
correlation between myometrial invasion and clinical prognosis. Increasing myometrial penetration is associated with 
an increasing risk of pelvic and para-aortic lymph node metastasis, adnexal metastasis, positive peritoneal cytology, 
local vault recurrence, and hematogenous spread. The causal role for Insulin-like growth factor-1 and insulin in 
endometrial carcinogenesis is well supported and insulin and IGF system have mitogenic and antiapoptotic activity. 
Endometrial cancer cell lines express high-affinity insulin receptors, consistent with there being a direct biological 
effect of insulin and IGF system on the growth and myometrial invasion of endometrial cancer cells. 
Material and methods: Patients with endometrial carcinoma have been divided into three groups: tumor confined 
to the endometrium (stage IA, n:24), endometrial carcinoma with a  minimal invasion (less than 50% of the 
myometrium; stage IB, n:32), and the control group (n:40). Demographic factors, estradiol and free IGF-1 plasma 
levels have been compared in all groups. 
Results: Lower Free IGF-1 plasma levels were found in patients with myometrial invasion when compared to the 
patients without myometrial invasion.
Conclusions: In the following work we have presented the current understanding of endometrial carcinoma, 
association between free IGF-1 plasma levels and myometrial invasion in patients with endometrial adenocarcinoma 
in terms of management and survival.
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Introduction	
With	 a	 lifetime	 risk	 among	 women	 of	 2-3%,	 endometrial	
cancer	 is	 the	most	 common	 pelvic	 gynecologic	malignancy	 in	
industrialized	 countries	 [1].	 Approximately	 75%	 of	 cases	 are	
diagnosed	at	an	early	stage,	with	 tumor	confined	to	 the	uterine	
corpus.	Although	most	patients	are	cured	by	surgery	alone,	about	
15-20%	with	no	signs	of	locally	advanced	or	metastatic	disease	at	
primary	treatment	recurs,	with	limited	responsiveness	to	systemic	
therapy	[2].
Prognostic	 factors	 in	 early	 stage	 endometrial	 cancer	 are	
histological	type,	tumor	grade,	and	depth	of	myometrial	invasion.	
Myometrial	invasion	is	a	significant	prognostic	factor	in	Stage	I	
endometrial	carcinoma	as	it	defines	the	frequency	of	lymph	node	
metastases,	recurrence,	and	survival	from	disease.	Superficially	
invading	tumor	carries	a	risk	of	3-5%	for	pelvic	and	paraaortic	
lymph-node	metastasis,	while	deeply	invasive	tumor	increases	it	
substantially	to	17-25%	respectively	[3].
Obesity	 is	 a	major	 risk	 factor	 for	 endometrial	 cancer.	The	
relationship	 between	 obesity	 and	 endometrial	 cancer	 is	 due	 to	
elevated	serum	estradiol	and	insulin	levels.	IGF-1,	which	shares	
extensive	 amino	 acid	 sequence	 homology	 and	 downstream	
signaling	pathways	with	insulin,	has	similarly	garnered	research	
interest	 as	 a	 potential	 risk	 factor	 for	 endometrial	 cancer,	
especially	 because	 insulin-like	 growth	 factor-1	 (IGF-1)	 has	
much	stronger	mitotic	and	antiapoptotic	activity	than	insulin	[4].	
Within	endometrial	tissue,	IGF-1	may	mediate	the	proliferative	
effects	of	estrogen.	IGF-I	are	produced	not	only	in	the	liver,	by	
far	 the	major	 source	 of	 the	 peptide	 in	 the	 circulation,	 but	 also	
by	most	other	tissues,	including	the	endometrium.		IGF-I	levels	
in	the	blood	circulation	mainly	circulates	bound	to	IGF-binding	
proteins	(IGFBP).	Only	1%	of	IGF-1	circulates	free	in	the	serum.	
However,	 as	with	 estrogen,	 the	 free	 fraction	may	 be	 the	most	
biologically	active	form	of	IGF-1	[5].	
IGF-1	and	IGF-2	are	expressed	 in	 the	endometrial	stromal	
cells,	 and	 their	 expression	 is	 associated	 with	 endometrial	
differentiation.
Higher	levels	of	IGF-1	have	been	associated	with	an	increased	
risk	of	a	number	of	epithelial	cancers	[6].	Correlations	between	
higher	estrogen	levels	and	IGF-1	expression	and	between	higher	
progesterone	levels	and	IGFBP-1	levels	provide	a	potential	link	
between	the	IGF	system,	the	estrogen-progesterone	balance,	and	
endometrial	cancer	risk	[7].	
Epidemiological	 studies	 have	 shown	 evidence	 for	 a	
relationship	between	high	circulating	levels	of	insulin	like	growth	
factors	and	the	increased	risk	of	several	cancers,	including	breast,	
colon,	prostate,	lung,	cervix,	endometrium	cancer	[8].
Objectives	
We	 present	 the	 current	 understanding	 of	 endometrial	
adenocarcinoma,	association	between	 free	 IGF-1	plasma	 levels	
and	myometrial	 invasion	 in	 terms	 of	 patient	 management	 and	
survival.
Materials	and	methods
The	 case	 control	 study	 was	 conducted	 on	 patients	 who	
were	 hospitalized	 and	 underwent	 surgery	 for	 endometrial	
adenocarcinoma	at	Gynecologic	Oncology	Department	of	Izmir	
Ataturk	 Training	 and	 Research	 Hospital,	 between	 2006-2009.	
The	control	group	consisted	of	patients	from	the	same	age	group,	
with	no	history	of	cancer,	who	came	to	Outpatient	Clinic	due	to	
benign	gynecological	diseases.	Patients	who	were	enrolled	into	
the	study	signed	an	informed	consent.	
Fasting	 serum	samples	were	collected	preoperatively	 from	
patients	 with	 endometrial	 cancer	 and	 also	 for	 in	 outpatient	
department	from	controls.	In	all	cases	serum	concentration	of	the	
free	 IGF-1	was	measured	using	ELISA	by	DSL,	Webster,	TX® 
kits.
	 Streszczenie
Wstęp: Rak trzonu macicy jest częstym nowotworem narządu rodnego. Istnieje zależność pomiędzy stopniem 
naciekania macicy a rokowaniem. Wraz z zaawansowaniem nacieku na ścianę mięśniową macicy wzrasta ryzyko 
wystąpienia przerzutów do węzłów chłonnych miednicy i okołoaortalych, nacieku na przydatki, wznów w obrębie 
sklepienia pochwy, obecności komórek nowotworowych w badaniach cytologicznych płynu z jamy otrzewnowej 
oraz rozsiewu komórek nowotworowych za pośrednictwem krwi. 
Insulina i insulinopodobny czynnik wzrostu (IGF-1) pobudzają komórki do rozrostu, mają właściwości 
antyapoptotyczne oraz są znanymi czynnikami ryzyka raka trzonu macicy. Jednocześnie komórki nowotworowe 
wywodzące się z endometrium wykazują wysoką ekspresję receptorów o silnym powinowactwie wobec insuliny.
Materiał i metodyka: Pacjentki z rakiem endometrium podzielono na 3 grupy: chore z rakiem ograniczonym do 
endometrium (n:24), następnie pacjentki, u których naciek nie przekraczał ½ grubości ściany mięśniowej (n:32) 
i grupę kontrolną (n:40). U pacjentek analizowano czynniki demograficzne, badano poziom estradiolu i IGF-1 
w surowicy krwi.
Wyniki: Poziomy IGF-1 w surowicy krwi były niższe u pacjentek z obecnym naciekiem ściany mięśniowej 
w porównaniu z chorymi z naciekiem ograniczonym do endometrium.
Wnioski: Przedstawiliśmy obecną wiedzę na temat raka trzonu macicy, zależności pomiędzy poziomem wolnego 
IGF-1 w surowicy krwi a stopniem naciekania na ścianę endometrium u pacjentek z rakiem endometrium, pod 
kątem postępowania i przeżycia chorych.
 Słowa kluczowe: insulinopodobny czynnik wzrostu / rak endometrium / 
     / naciekiem na ścianę mięśniową / 
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The	results	of	the	patients	with	endometrial	adenocarcinoma	
were	 evaluated	 and	 divided	 into	 two	 groups,	 according	 to	 the	
histopathological	 results.	 First	 group	 consisted	 of	 patients	
whose	 endometrial	 carcinoma	 confined	 to	 the	 endometrium	
alone	 (International	 Federation	 of	 Gynecology	 and	 Obstetrics;	
stage	 IA,	Grade	 I),	while	 the	 second	group	comprised	patients	
with	 minimal	 invasion	 (less	 than	 50%	 of	 the	 myometrium;	
stage	 IB,	Grade	 I).	 Patients	with	 advanced	 stage	 endometrium	
carcinoma	were	excluded	due	to	its	low	incidence.	Demographic	
factors	such	as	age,	height,	weight,	body	mass	index,	parity	and	
postmenopausal	period	were	recorded	individually	for	each	case.	
Exclusion	criteria	were	alike	 for	all	groups	of	patients:	current	
and	 previous	 hormone	 replacement	 therapy,	 diabetes	 mellitus	
together	with	other	metabolic	systemic	diseases,	and	endometrial	
carcinoma	at	an	advanced	stage	and	grade.
Statistical	 analyses	 were	 made	 using	 SPSS	 16.0	 software	
program	and	parametric	data	was	tested	for	its	normal	distribution.	
Mean	 and	 standard	 deviation	 of	 continued	 variables	 were	
calculated.	Time	after	the	menopause,	BMI,	and	plasma	estradiol	
level	were	tested	with	student-t	and	one	way	ANOVA	tests.	Age,	
parity,	height,	weight,	and	plasma	free	IGF-1	levels	of	the	patients	
were	 compared	 by	 means	 of	 Mann-Whitney-U	 and	 Kruskal	
Wallis	ANOVA	tests.	Spearman’s	test	was	used	to	investigate	the	
correlation	between	myometrial	invasion	and	variables.	Logistic	
Regression	Analysis	determined	the	significance	of	the	variables.	
A	value	of	p<0.005	was	considered	statistically	significant.
Results
56	 patients	 who	 had	 been	 diagnosed	 with	 stage	 IA	 and	
IB	 endometrial	 carcinoma	 were	 included	 into	 our	 study.	 24	
patients	 with	 tumors	 confined	 to	 the	 endometrium	 (stage	 IA)	
comprised	the	first	group.	32	patients	with	tumors	invading	less	
than	50%	of	myometrial	invasions	constituted	the	second	group	
(stage	IB).	The	control	group	consisted	of	40	patients	suffering	
from	 various	 benign	 gynecological	 diseases.	All	 patients	 were	
postmenopausal.
The	mean	and	standard	deviations	of	the	patients	regarding	
age,	 BMI,	 time	 after	 the	menopause,	 parity,	 estradiol	 and	 free	
IGF-1	 levels	 are	 presented	 in	 Table	 I.	 Binary	 comparison	 of	
the	 variables	 (control	 group	 versus	 patients	 with	 endometrial	
adenocarcinoma,	 and	 patients	 with	 stage	 IA	 endometrial	
adenocarcinoma	 versus	 patients	 with	 stage	 IB	 endometrial	
adenocarcinoma)	are	summarized	in	Table	I.	
Results	 for	binary	and	 trinity	analysis	of	variables	showed	
no	statistically	significant	difference	between	these	three	groups	
except	for	free	plasma	IGF-1	levels.	As	far	as	the	IGF-1	levels	
are	 concerned,	 free	 IGF-1	 plasma	 levels	 of	 the	 patients	 with	
endometrial	 carcinoma	 were	 found	 to	 be	 lower	 than	 those	 of	
patients	without	endometrial	carcinoma.	Similarly,	the	results	of	
patients	with	 stage	 IB	 endometrial	 carcinoma	were	 also	 lower	
than	in	case	of	stage	IA.	The	difference	between	the	free	IGF-1	
plasma	levels	of	the	groups	was	statistically	significant	(p:0.001,	
p<0.001	respectively).	
Table I. Free IGF-1 and other variables in three different groups of patients (control group and, endometrial adenocarcinoma group with or without myometrial invasion)
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The	 correlation	 between	 myometrial	 invasion	 and	
demographic	 data	 and	 IGF	 levels	was	 investigated.	There	was	
weak	 correlation	 between	 BMI	 and	 free	 IGF-1	 plasma	 levels	
(rho:0.297,	p<0.028),	and	moderate	correlation	between	free	IGF-
1	plasma	levels	and	myometrial	invasion	(rho:-0.490,	p<0.001).	
According	 to	 these	 findings,	 there	 is	 logarithmic	 correlation	
between	increasing	levels	of	free	plasma	IGF-1	and	BMI.	Also,	
there	 is	 a	 negative	 correlation	 between	 decreasing	 free	 IGF-1	
plasma	levels	and	myometrial	invasion.	LRA	(Logistic	Regression	
Analysis)	allows	us	 to	estimate	 that	 free	 IGF-1	plasma	 level	 is	
one	 of	 the	 most	 important	 markers	 for	 predicting	 myometrial	
invasion	of	endometrial	carcinoma.
Discussion
In	 this	 prospective	 case	 control	 study	 the	 plasma	 levels	
of	 free	 IGF-1	 were	 evaluated	 in	 patients	 with	 or	 without	
endometrial	 carcinoma.	 Postmenopausal	 patients	with	 an	 early	
stage	endometrial	carcinoma	which	have	similar	age,	BMI,	and	
estradiol	 levels	 were	 found	 to	 have	 lower	 free	 IGF-1	 levels.	
In	 endometrial	 carcinoma	 groups,	 the	 free	 IGF-1	 levels	 of	 the	
patients	with	myometrial	invasion	were	found	to	be	lower	than	of	
those	with	endometrial	carcinoma	confined	to	the	endometrium.	
Numerous	 epidemiological	 studies	 have	 shown	 evidence	
for	a	relationship	between	high	circulating	levels	of	insulin-like	
growth	factors	(IGFs)	and	an	increased	risk	of	several	cancers.	
Most	 of	 IGF-I	 in	 the	 circulation	originates	 from	 the	 liver.	The	
main	physiological	stimulus	for	hepatic	IGF-I	synthesis	is	growth	
hormone.	The	only	unbound	and	free	fraction	is	1%	of	total	and	
acts	in	an	autocrine	or	paracrine	fashion.	In	our	study,	we	have	
focused	 exclusively	 on	 free	 IGF-1	 levels	 in	 our	 patients.	 In	
endometrial	tissue,	however,	estrogens	provide	the	main	stimulus	
for	IGF-1	synthesis.	Given	these	differences	in	physiology,	it	is	
quite	possible	that,	contrary	to	several	other	forms	of	cancer	[9],	
endometrial	 cancer	 risk	 is	 relatively	 independent	of	 circulating	
IGF-I	levels.
Circulating	 IGF-1	 levels	 change	 substantially	 by	 age,	
increasing	slowly	from	birth	to	puberty,	surging	in	puberty,	and	
declining	with	age	thereafter	[10].	On	the	other	hand,	individual	
levels	of	free	IGF-1	are	known	to	be	stable	over	postmenopausal	
years, and	failure	to	have	optimally	detected	variations	in	serum	
values	would	most	likely	have	caused	bias	toward	the	null	[11].	
In	our	study,	all	of	 the	patients	were	postmenopausal	and	there	
was	no	difference	in	the	mean	age	of	the	enrolled	cancer	cases	
and	the	controls.	
IGF-1	 expression	 was	 significantly	 decreased	 in	 the	
myometrium	by	age,	which	we	have	previously	shown	to	become	
proliferatively	 quiescent	 [11].	 In	 our	 study,	 all	 patients	 were	
postmenopausal	and	had	limited	ability	to	stimulate	endometrial	
cell	proliferation,	so	plasma	IGF-1	could	act	as	such	a	survival	
factor	 by	 inhibiting	 apoptosis.	 A	 recent	 study	 that	 directly	
measured	 IGF-1	 mRNA	 levels	 in	 human	 endometrial	 cancer	
specimens	(rather	than	in	cell	lines)	found	IGF-1	mRNA	levels	
to	be	low	[12].
Obese	 individuals	 are	 presumed	 to	 be	 at	 higher	 risk	 for	
the	 development	 of	 endometrial	 cancer	 due	 to	 the	 increased	
bioavailability	 of	 estrogen.	 Free	 and	 total	 plasma	 levels	 of	 
IGF-2	 were	 found	 to	 be	 increased	 in	 both	 non-diabetic	 obese	
cases	and	type	2	diabetics,	whereas	IGF-1	remained	unchanged	
[13].	However,	although	the	control	group	was	not	BMI-matched	
with	the	rest	of	the	subjects,	it	was	found	similar	to	the	BMI	of	the	
endometrial	cancer	groups.	We	found	week	positive	correlation	
between	BMI	and	IGF-1	levels.
Gunter	MJ	et	al.	found	that	estradiol	level	itself	was	positively	
associated	with	endometrial	cancer	risk,	even	after	adjustment	for	
free	IGF-1,	BMI,	and	age.	IGF-1	was	not	significantly	associated	
with	the	risk	for	endometrial	cancer	[4].	In	our	study	we	found	
no	 difference	 in	 the	 levels	 of	 estradiol	 between	 stage	 IA,	 IB	
endometrial	carcinoma	and	the	controls.	
IGF-1	 pathway	 plays	 an	 important	 role	 in	 the	 normal	
endometrial	 glandular	 and	 stromal	 cell	 proliferation	 [8].	 At	
carcinogenesis,	despite	a	very	clear	evidence	to	support	the	direct	
role	of	 insulin	 in	endometrial	 tumorigenesis,	 it	 is	 also	possible	
that	insulin	like	growth	factor	is	simply	a	presenting	clinical	and	
pathological	 marker	 of	 endometrial	 cancer	 development	 and	
invasion.	
There	is	a	strong	correlation	between	disease	mortality	and	
depth	 of	myometrial	 invasion	 in	 endometrial	 cancer. Depth	 of	
invasion	is	a	well-established	prognostic	factor	in	stage	I	cases,	
as	 it	 defines	 the	 risk	 and	 existence	 of	 lymph-node	metastases,	
recurrence,	 and	 survival	 from	 the	 disease	 [1]. A	 superficially	
invading	 tumor	 (less	 than	 50%	 of	 the	 myometrium)	 carries	 a	
risk	of	5%	and	3%	for	pelvic	and	paraaortic	node	metastasis,	in	
contrast,	 among	deeply	 invasive	 tumor	 (more	 than	50%	of	 the	
myometrium)	 the	 risk	 increases	substantially	 to	25%	and	17%,	
respectively	 [1]. Recognition	 of	 the	 prognostic	 significance	 of	
myometrial	invasion,	in	addition	to	other	factors	as	well,	led	to	
the	adoption	of	surgical	staging	in	Endometrial Cancer by FIGO 
(International Federation of Gynecologists and Obstetricians)	in	
1988. 
The	clinic-based	studies	directly	evaluated	circulating	IGFs	
and	IGFBPs	in	women	with	and	without	endometrial	cancer.	The	
results	of	these	studies	conflicted.	The	patients	with	and	without	
endometrial	cancer	were	compared	in	the	study	of	Rutanen	EM	
et	al,	and	they	found	lower	IGF-1,	IGF-2	and	IGFBP3	levels	in	
patients	with	endometrial	cancer	[14].	
Petridou	et	al	compared	the	cases	of	histologically	confirmed	
endometrial	 cancer	 with	 a	 control	 group	 of	 women	 who	 had	
undergone	minor	gynecological	operations	[15].	They	found	that	
endometrial	 cancer	 was	 positively	 associated	 with	 IGF-2	 and	
inversely	with	IGF-1.
In	the	study	by	Lukanova,	which	included	primary	invasive	
endometrial	 cancer	 and	 matched	 controls,	 it	 was	 shown	 that	
endometrial	 cancer	 risk	 increased	 with	 increasing	 level	 of	
c-peptide	and	 IGFBP-1,	but	 the	 risk	was	unrelated	 to	 levels	of	 
IGF-1	[9].	Weiderpass	E.	et	al	also	presented	in	their	study	that	
serum	IGF-1,	IGFBP-1,	IGFBP-3	and	insulin	levels	seem	unrelated	
to	endometrial	cancer	risk	[16].	Lacey	JV	et	al	also	suggested	that	
serum	IGF-1	was	 inversely	associated	with	endometrial	cancer	
[17].	Oh	CJ	et	al	demonstrated	similar	findings	as	 in	our	study	
that	the	mean	values	of	IGF-1	were	significantly	lower	among	the	
studied	cases	than	controls	[18].
On	 the	 other	 hand,	 Ayabe	 et	 al	 compared	 IGF-1	 and	
IGFBP-1	levels	in	women	with	and	without	endometrial	cancer	
and	they	concluded	that	an	increased	circulating	concentration	of	
IGF-1	 and	decreased	 circulating	 concentration	of	 IGFBP-1	 are	
associated	with	endometrial	cancer,	especially	in	postmenopausal	
women	[19].	The	BMI	was	significantly	higher	in	the	endometrial	
cancer	group	than	in	the	control	group.
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In	 our	 study,	 the	 counter	 correlation	 between	 free	 plasma	 
IGF-1	and	myometrial	invasion	was	surprising,	particularly	given	
our	 a	 priori	 hypothesis	 that	 predicted	 a	 positive	 relationship,	
in	 keeping	 with	 the	 mitogenic	 effects	 of	 plasma	 IGF-1	 in	
myometrial	tissue.	In	the	present	study,	IGF	levels	are	decreased	
when	 myometrial	 invasion	 exists.	 The	 seemingly	 paradoxical	
inverse	 association	of	 free	 IGF-1	and	myometrial	 invasion	has	
several	 potential	 explanations.	 A	 disconnection	 between	 local	
uterine	IGF-1	levels	and	IGF-I	levels	in	circulation	is	believed	to	
exist.	Autocrine	IGF-1	signaling	may	be	an	important	regulator	
of	tissue	growth	in	the	normal	myometrium	and	that	dysregulated	
expression	of	growth	factor	is	observed	in	uterine	cancers.	
Conclusions	
As	a	summary,	our	data	suggests	that	IGF	levels	increased	
when	BMI	 increased.	 In	 the	 existence	of	myometrial	 invasion,	
free	IGF-1	plasma	levels	decreased.		
Free	 IGF-1	plasma	 levels	would	probably	be	an	 important	
factor	 determining	myometrial	 invasion	 in	 endometrial	 cancer.	
To	the	best	of	our	knowledge,	our	study	is	the	first	prospective	
study	 in	 the	 literature	which	evaluates	 the	 association	between	
myometrial	 invasion	 and	 IGF-1	 levels	 in	 endometrial	 cancer	
patients.	
A	 much	 larger	 further	 prospective	 cohort	 studies	 of	
endometrial	 cancer	 should	 be	 conducted,	 accompanied	 by	
continuous	efforts	to	better	understand	and	clarify	the	role	of	free	
IGF-1	plasma	levels	in	endomyometrial	invasion	of	tumors.	
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